Table II.
Clinical characteristics at the time of diagnosis according to histopathological examination.
| Variable | Active n=16 | Borderline n=10 | P-value |
|---|---|---|---|
| Clinical symptoms | |||
| Dyspnea, n (%) | 8 (50) | 7 (70) | 0.428b |
| Chest pain, n (%) | 10 (62.5) | 6 (60) | 0.609b |
| Palpitations, n (%) | 6 (37.5) | 1 (10) | 0.190b |
| Syncope, n (%) | 5 (31.3) | 2 (20) | 0.668b |
| Functional class (NYHA) | |||
| CF-I–II, n (%) | 13 (81.3) | 9 (90) | 0.496b |
| CF III–IV, n (%) | 3 (18.8) | 1 (10) | 0.496b |
| Physical findings upon exploration | |||
| Cardiac frequency (bpm) median (range) | 90 (30–130) | 67 (40–88) | 0.015a,d |
| Hypotension, n (%) | 0 | 2 (20) | 0.138b |
| Rales, n (%) | 4 (25) | 3 (30) | 0.562b |
| Laboratory findings | |||
| Maximum troponin, median (range) (ng/ml) | 2.4 (0.01–30) | 0.05 (0.1–13.3) | 0.238a |
| Total CPK maximum, median (range) (U/l) | 595 (56–2,444) | 185.5 (63–1,690) | 0.350a |
| Total CPK-MB maximum, median (range) (Ul) | 46.5 (1–301) | 22 (15.4–138) | 0.433a |
| Electrocardiograph findings | |||
| Prolonged QRS (>120 m sec), n (%) | 6 (37.5) | 4 (40) | 0.609b |
| AV blockage, n (%) | 4 (25) | 2 (20) | 0.580b |
| Tachyarrhythmia, n (%) | 8 (50) | 2 (20) | 0.218b |
| Echocardiograph findings | |||
| LVEF (%) median (range) | 35 (13–57) | 60 (31–70) | 0.005a,e |
| LVEF <45%, n (%) | 8 (50) | 5 (50) | 0.656b |
| Right ventricular dysfunction, n (%) | 4 (25) | 3 (33) | 0.673b |
| Ventricular dysfunction, n (%) | 9 (56) | 5 (50) | 0.756c |
| PASP (mmHg) median (range) | 30.5 (17–46) | 37.5 (25–50) | 0.053a |
| TAPSE (mm) median (range) | 18 (11–27) | 21,5 (19–26) | 0.017a,d |
a
Mann-Whitney U test.
b
Fisher exact test.
c
Pearson Chi squared.
d
P<0.05
e
P<0.01. NYHA, New York Heart Association; CF, Functional class; bpm, beats per minute; CPK, Creatine phosphokinase; MB, isoform muscle/brain; AV, atrioventricular; LVEF, Left ventricular ejection fraction; PSAP, Pulmonary artery systolic pressure; TAPSE, Tricuspid annular plane systolic excursion.